Experts in health care policy reached a consensus on a set of concrete, feasible steps that show promise for slowing spending growth and improving quality in health care.

Mark B. McClellan, M.D., testifies before the U.S. House of Representatives Budget Committee on Medicare Advantage and the federal budget.

The most sweeping reforms since 1997 are planned this year for theFDAin order to address the concern that it is not protecting the public from drugs' risks as effectively as it might.

The greatest opportunities for improvement of drug safety are in the post-market process.

AEI-Brookings Joint Center senior fellow Judyth Pendell interviews FDA commissioner Mark B. McClellan about liability, innovation, and policy objectives.

Cosponsored by AEI and the Engelberg Center for Health Care Reform at Brookings Institution, this conference on regulating medical devices will convene stakeholders to discuss current challenges and feasible solutions that protect public health while encouraging the development, approval, and reimbursement of effective technologies.

If mergers reduce competition and reduce excess capacity, policy analysis should balance these two consequences in deciding whether and how a merger should be approved.

Instrumental variablesanalysis may be well suited to a range of applications, and they deserve a slot in the health services researcher's toolkit.